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Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about
reproducibility in scientific research by conducting replicating selected results from a number of
high-profile papers in the field of cancer biology. The papers, which were published between 2010
and 2012 were selected on the basis of citations and Altimetric scores (Errington et al., 2014). This
Registered report describes the proposed replication plan of key experiments from ‘Biomechanical
remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis’ by
Goetz and colleagues, published in Cell in 2011 (Goetz et al., 2011). The key experiments being
replicated are those reported in Figures 7C (a-d), Supplemental Figure S2A, and Supplemental
Figure S7C (a-c) (Goetz et al., 2011). In these experiments, which are a subset of all the experiments
reported in the original publication, Goetz and colleagues show in a subcutaneous xenograft model
that stromal caveolin-1 remodels the intratumoral microenvironment, which is correlated with
increased metastasis formation. The Reproducibility Project: Cancer Biology is a collaboration
between the Center for Open Science and Science Exchange and the results of the replications will
be published in eLife.
DOI: 10.7554/eLife.04796.001
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The importance of the tumor microenvironment in cancer progression is well established. Cancerassociated fibroblasts (CAFs) are one subset of cells found in the tumor stroma that help to regulate
tumor progression and metastasis through several mechanisms such as remodeling of the extracellular
matrix, secretion of growth factors and chemokines, and regulation of epithelial-to-mesenchymal
transition (Kalluri and Zeisberg, 2006; Cirri and Chiarugi, 2011). Caveolin-1 (Cav1) is an essential
component of caveolae and regulator of lipid raft formation that plays an important role in tumor
progression (Goetz et al., 2008; Sotgia et al., 2012). However, the precise role of Cav1 in tumor
progression appears to be unclear, with studies showing both increased and decreased expression in
various types of cancer (Parton and del Pozo, 2013). One possible model is a general trend in which
Cav1 appears to act as a tumor suppressor at early stages of cancer progression, but is up-regulated
in several multidrug-resistant and metastatic cancer cell lines and human tumor specimens, positively
correlating with tumor stage and grade in numerous cancer types (Shatz and Liscovitch, 2008). Part
of this variability could stem from Cav1 expression in stromal rather than tumor cells. For instance, loss
of Cav1 function in stromal cells of various organs leads to benign stromal lesions responsible for
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abnormal growth and differentiation of the epithelium and to dramatic reductions in life span (Yang
et al., 2008). Goetz and colleagues, reported that Cav1 expression in fibroblasts remodeled the
extracellular matrix to regulate cell shape and to stimulate migration and invasion of cancer cells in
vitro, and promote tumor growth and metastasis in vivo in a p190RhoGAP dependent manner (Goetz
et al., 2011).
In order to specifically assess the role of Cav1 in the tumor stroma on intratumoral
microenvironment remodeling and metastasis, Goetz and colleagues utilized a subcutaneous
xenograft model in which primary mouse embryonic fibroblasts (pMEFs) derived from either wild
type (WT) or Cav1 knock out animals (Cav1 KO) were coinjected subcutaneously with luminescent LM4175 metastatic breast tumor cells (Minn et al., 2005) with Matrigel into nude mice (Goetz et al.,
2011). Figure 7Ca presents a graphical illustration of the experimental procedure. Primary tumor
growth and metastatic tumor growth was assessed by bioluminescent imaging in vivo or ex vivo in
extracted organs. Further, immunostaining of primary tumors was utilized to analyze the fiber
alignment and organization of the tumor stroma in the presence of WT or Cav1 KO pMEFs, as
alignment of collagen fibers in the tumor microenvironment has been shown to enhance tumor cell
migration and invasion (Amatangelo et al., 2005; Provenzano et al., 2006). It is important to note
that the authors also performed shRNA knock down of p190RhoGAP in Cav1 KO pMEFs to show that
the effects of Cav1 KO on metastasis could be reversed by knock down of p190RhoGAP in Cav1 KO
pMEFs. This replication study will only address the effects of Cav1 expression in tumor stroma and
remodeling of the tumor microenvironment matrix, and will not replicate the effects of p190RhoGAP
in this model.
These experiments utilize isolated WT or Cav1 KO pMEFs, which are generated in Protocol 1. The
loss of Cav1 in the Cav1 KO pMEFs (Figure 7Ca), lead to an increase in smooth muscle actin (SMA)
compared to Cav1 WT pMEFs, which is an indicator of increased activation and extra cellular matrix
(ECM) remodeling capabilities of the generated pMEFs (Supplemental Figure S2A) (Goetz et al.,
2011). These pMEFs were used in a subcutaneous tumorigenicity assay, with representative
bioluminescent images of primary tumors in vivo or ex vivo in extracted organs reported in
Figure 7Cc. Bioluminescence of the primary tumors or metastatic foci in each organ was quantified
and shown in Figure 7Cb or Supplemental Figure S7Ca. Goetz and colleagues evaluated metastatic
tumor growth where they reported an increase in metastatic foci when tumor cells were coinjected
with WT pMEFs compared to tumor cells alone or tumor cells coinjected with Cav1 KO pMEFs
(Goetz et al., 2011). While not the main focus of this experiment they did not observe a difference
in primary tumor growth between these conditions (Goetz et al., 2011). This experiment is
important to replicate because it tests the central tenet of the paper, namely that Cav1 expression in
stromal fibroblasts contributes to increased metastasis of tumors. This experiment is replicated in
Protocol 3.
Although there was no observed difference in primary tumor growth when Cav1 was absent in the
tumoral stroma specifically, a decrease in primary tumor growth was observed when the whole
mammary gland was deficient for Cav1 in mammary gland allografts and xenografts (Goetz et al.,
2011). In a related study, subcutaneous injection of B16 melanoma cells in Cav1 KO mice resulted in
a reduced tumor growth compared to injection of tumor cells in WT mice (Chang et al., 2009).
Another study, which focused on the size of the primary tumors opposed to metastasis, reported that
intradermal coinjection of nude mice with B16F10 melanoma cells and Cav1 KO neonatal dermal
fibroblasts increased primary tumor growth when compared to coinjection of tumor cells with WT
fibroblasts (Capozza et al., 2012). While no known direct replications of the original study have been
reported, several studies have assessed the role of stromal Cav1 expression in different types of
tumors, with some studies reporting high Cav1 expression correlated with poor patient survival (Linke
et al., 2010; Goetz et al., 2011; Righi et al., 2014), and others reporting low Cav1 expression in the
stroma negatively correlated with survival (Simpkins et al., 2012; Ma et al., 2013; Zhao et al., 2013;
Ren et al., 2014).
Figure 7Cc and Supplemental Figure S7Cb show representative images of tumor sections
immunostained for fibronectin, the CAF marker SMA, and nuclei. Goetz and colleagues showed that
fibronectin fiber alignment increased in the presence of Cav1 (Goetz et al., 2011). Supplemental
Figure S7Cc shows the results of quantification of fibronectin and SMA fiber alignment as well as cell
shape. Goetz and colleagues also show in Figure 7Cd that metastasis correlates with the degree of
fibronectin fiber alignment in the tumor stroma. These figures are important to replicate as they show
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that Cav1 expression in fibroblasts contributes to remodeling of the tumor microenvironment in vivo,
and that this remodeling correlates with the amount of metastasis. These experiments are replicated
in Protocol 4.

Materials and methods
Protocol 1: isolation of Cav1 WT and Cav1 KO primary MEFs
This experiment describes the isolation of primary MEFs (pMEFs) that will subsequently be used in
Protocols 2 and 3.

Sampling
■ Each experiment has 2 cohorts:
○ Cohort 1: Cav1-WT embryos.
○ Cohort 2: Cav1-KO embryos.
■ Experiment performed with three pregnant females in each cohort to ensure enough pMEFs are
obtained.
○ Power calculations are not applicable.

Materials and reagents
Reagent

Type

Manufacturer

Catalog #

Comments

6–8 week old B6129SF2/J mice
(Cav1 WT)

Animal model

Jackson laboratory

101045

1 male and 3 females for breeding

6–8 week old CAV1<tm1mls>/J mice
(Cav1 KO)

Animal model

Jackson laboratory

004585

1 male and 3 females for breeding

Ethanol

Chemical

Sigma–Aldrich

E7023

Original not specified

PBS, without MgCl2 and CaCl2

Buffer

Sigma–Aldrich

D8537

Original not specified

0.05% trypsin/0.48 mM EDTA

Cell culture

Sigma–Aldrich

T3924

Original not specified

50 ml tubes

Labware

Sigma–Aldrich

CLS430290

Original not specified

Dulbecco’s modified Eagle’s
medium—low glucose, without
L-glutamine

Cell culture

Sigma–Aldrich

D5546

Original not specified

Fetal bovine serum

Cell culture

Sigma–Aldrich

F0392

Original not specified

L-glutamine

Cell culture

Sigma–Aldrich

G7513

Original not specified

100× Pen/Strep

Cell culture

Sigma–Aldrich

P4333

Original not specified

150 mm tissue culture dishes

Labware

Sigma–Aldrich

CLS430599

Original not specified

100 mm tissue culture dishes

Labware

Sigma–Aldrich

CLS430167

Original not specified

60 mm tissue culture dishes

Labware

Sigma–Aldrich

CLS430166

Original not specified

Procedure
Notes
c
c

This protocol contains information described in Cerezo et al. (2009), Razani et al. (2001), and
Kamijo et al. (1997).
pMEFs grown in complete DMEM: DMEM supplemented with 10% FBS, 2 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere at
5% CO 2 .
1. Sacrifice E14.5 pregnant Cav1WT (B6129SF2/J) and Cav1KO (CAV1<tm1mls>/J) mouse by
cervical dislocation.
2. Dissect uterine horns and transfer to tube with ice-cold PBS to a tissue culture hood.
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3. Transfer uterine horns to a 100 mm tissue culture dish; separate embryos from and discard
placenta and embryonic sac.
4. For each embryo, place in a dry 100 mm plate, dissect and discard head and red organs.
5. Mince with sterile scissors or a sterile razor blade until homogeneous and pipettable.
6. Add 1 ml 0.05% trypsin/0.53 mM EDTA per embryo, disaggregate further by pipetting, and
incubate 5 min at 37˚C.
7. Plate 1 ml of cells/trypsin into 150 mm tissue culture dishes (one dish per embryo), and try to
further disaggregate by pipetting.
a. Ensure medium is pre-warmed before adding cells.
b. These are ‘passage 1’ cells.
8. Repeat the disaggregation with the pipette every 10 min, 3 or 4 times (steps 6–7).
9. Change the medium after 24 hr.
10. On day 3 and every third day thereafter, passage 3 × 105 cells per 60 mm dish.
a. Use pMEFs before passage 5.
11. Use pMEFs in further experiments below.
a. Western blot analysis of Cav1 and SMA levels (Protocol 2).
b. Subcutaneous tumorigenicity assay (Protocol 3).
12. Repeat for each pregnant mouse.

Deliverables
■ Data to be collected:
○ Mouse health records (gender of mice, age of embryos when sacrificed).
■ Sample delivered for further analysis:
○ pMEFs derived from Cav1WT and Cav1KO mouse embryos (Protocols 2 & 3).

Confirmatory analysis plan
This protocol will not perform any statistical tests.

Known differences from the original study
All known differences, if any, are listed in the materials and reagents section above with the originally
used item listed in the comments section. The comments section also lists if the source of original item
was not specified. All differences have the same capabilities as the original and are not expected to
alter the experimental design.

Provisions for quality control
All of the raw data, will be uploaded to the project page on the OSF (https://osf.io/7yqmp) and made
publically available.

Protocol 2: assessment of Cav1 and SMA levels in pMEFs by western
blot
This experiment assesses the protein levels of Cav1 to ensure the Cav1 KO pMEFs generated are
actually knockout for Cav1. Additionally, SMA is assessed to determine if levels in Cav1 KO pMEFs are
increased over Cav1 WT pMEFs, which indicate increased activation and ECM remodeling capabilities
of the generated pMEFs. It is similar to the experiments reported in Figure 7Ca and Supplemental
Figure S2A.

Sampling
c

c

c

Each experiment has two cohorts:
○ Cohort 1: Cav1-WT pMEFs.
○ Cohort 2: Cav1-KO pMEFs.
Each clone of pMEFs will be assessed for the following markers:
○ Cav1.
○ SMA.
○ γ-tubulin.
Experiment will be conducted once and used to assess which clones will be utilized.
○ Power calculations are not applicable.
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Materials and reagents
Reagent

Type

Manufacturer

Catalog #

60 mm tissue culture dishes

Labware

Sigma–Aldrich

CLS430166

Comments

PBS, without MgCl2 and CaCl2

Buffer

Sigma–Aldrich

D8537

RIPA lysis buffer

Buffer

Cell scraper

Labware

Specific brand information will be left up to the discretion of the replicating lab and
recorded later

Refrigerated centrifuge

Equipment

Bradford assay

Reporter assay

Molecular weight marker

Western materials

6× SDS-PAGE sample buffer

Buffer

SDS-PAGE gel

Western materials

Tris-glycine SDS-PAGE running buffer

Buffer

Original not specified

Specific brand information used to make these reagents will be left up to the discretion of
the replication lab and recorded later

Electrotransfer buffer

Buffer

Ponceau S stain

Stain

TBS buffer

Buffer

PVDF membrane

Western materials Specific brand information will be left up to the discretion of the replicating lab and
recorded later
Chemical

Tween-20
Non-fat dry milk

Western materials

ECL chemiluminescent reagent

Western materials

Mouse anti-Cav1 (clone 2297)

Antibodies

BD Biosciences

610406

Mouse anti-α-smooth muscle actin
(clone 1A4)

Antibodies

Sigma–Aldrich

A5228

Mouse anti-γ-tubulin (clone GTU-88)

Antibodies

Sigma–Aldrich

T6557

Goat anti-mouse-HRP

Antibodies

Life Sciences

32,430

Original clone/catalog# unspecified

Original clone/catalog # unspecified

Procedure
Note
c
c

pMEFs are generated in Protocol 1.
pMEFs maintained in: DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO2.
1. Prepare each clone of pMEFs for lysis.
a. Wash cells with ice-cold PBS and remove excess PBS.
b. Add cold RIPA buffer to cells (use 1 ml of buffer per 60 mm dish).
c. Keep on ice for 5 min, swirling plate occasionally for uniform spreading.
d. Collect lysate with cell scraper and transfer to microcentrifuge tube.
e. Centrifuge samples at ∼14,000×g for 15 min at 4˚C.
f. Transfer supernatant to new tube.
2. Determine protein concentration using Bradford assay following manufacturer’s instructions and
a BSA standard curve.
3. Adjust protein concentration and prepare up to 70 μg/lane of total cell lysate by adding 6×
SDS-PAGE sample buffer and heating to 100˚C for 5 min.
4. Separate samples and molecular weight marker by SDS-PAGE gel electrophoresis in 1× trisglycine SDS buffer following replicating lab’s protocol. Run at 100V through the stacking part of
the gel and up to 200 V after the proteins have migrated through the resolving gel. Allow
migration to continue until the blue dye front is at the bottom of the gel, but has not migrated off.
a. Include Cav1 WT and Cav1 KO clones on same gel to allow comparison.
5. Transfer gel to a PVDF membrane, following replicating lab’s transfer procedure.
6. After the transfer, stain the membrane with Ponceau S to visualize the transferred protein. Image
membrane, than destain in ddH2O and rinse with TBS buffer.
7. Incubate membrane with 5% non-fat dry milk in TBST buffer.
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a. TBST buffer: TBS with 0.1% Tween-20.
8. Probe membrane with the following primary antibodies diluted in 5% non-fat dry milk in TBST
buffer:
a. mouse anti-Cav1; use at 1:1000; 21 kDa.
b. mouse anti-SMA; use at 1:1000; 42 kDa.
c. mouse anti-γ-tubulin; use at 1:1000; 48 kDa.
9. Wash membrane in TBST buffer.
10. Detect primary antibodies with the following secondary antibody diluted in 5% non-fat dry milk in
TBST buffer:
a. anti-mouse-HRP; use at 1:5000 to 1:10,000.
11. Wash membrane in TBST buffer.
12. Detect signal with ECL reagent following manufacturer’s instructions.
13. Image the entire membrane including molecular weight ladder.
14. Quantify signal intensity.
a. For each antibody subtract background intensity from values and then divide by the γ-tubulin
loading control.
b. Calculate the normalized SMA levels for all clones.
c. Confirm absence of Cav1 protein in all Cav1 KO pMEFs.
15. Exclude any clones that do not display a presence (Cav1 WT pMEFs) or absence (Cav1 KO pMEFs)
of Cav1. Exclude any clones that do not have an increase in SMA expression with a loss of Cav1
(Cav1 KO pMEFs compared to Cav1 WT pMEFs).
16. Use remaining pMEF clones in further experiments before passage 5:
a. Subcutaneous tumorigenicity assay (Protocol 3).

Deliverables
■ Data to be collected:
○ Images of probed membranes (full images with ladder).
○ Raw and quantifed signal intensities normalized for γ-tubulin loading and total protein levels.
■ Sample delivered for further analysis:
○ Cav1 WT and Cav1 KO pMEFs that are included for further use (Protocol 3).

Confirmatory analysis plan
This protocol will not perform any statistical tests.

Known differences from original study
The replicating lab western blot protocol will be used. All known differences, if any, are listed in the
materials and reagents section above with the originally used item listed in the comments section. The
comments section also lists if the source of original item was not specified. All differences have the
same capabilities as the original and are not expected to alter the experimental design.

Provisions for quality control
Transfer quality will be assured by Ponceau staining. All of the raw data, will be uploaded to the
project page on the OSF (https://osf.io/7yqmp) and made publically available. This experiment is also
the quality control for the pMEFs generated in Protocol 1 that will be utilized in Protocol 3 to assess
Cav1 status and ECM remodeling capabilities.

Protocol 3: subcutaneous tumorigenicity assay of tumor cells co-injected
into athymic nude mice with pMEFs
This experiment tests the contribution of Cav1 expression in pMEFs on tumorigenicity and metastasis
of breast cancer cells. pMEFs derived from WT or Cav1 KO animals are co-injected with LM-4175
breast cancer cells in a Matrigel plug subcutaneously in nude mice and tumor growth and metastasis
are monitored by bioluminescent imaging. It is a replication of the experiment reported in Figure 7Cb
and Supplemental Figure S7Ca.

Sampling
■ Experiment has 3 cohorts:
○ Cohort 1: LM-4175 cells alone.
○ Cohort 2: LM-4175 cells co-injected with Cav1 WT pMEFs.
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○ Cohort 3: LM-4175 cells co-injected with Cav1 KO pMEFs.
■ Experiment will analyze the following number of mice per cohort for a minimum power of 80%:
○ See Power calculations section for details.
c Cohort 1: 7 mice.
c Cohort 2: 21 mice.
c Cohort 3: 21 mice.
■ To account for unexpected euthanasia of mice before the end of the experiment, 20% more mice
were added to ensure the needed number of mice survive each cohort:
○ Cohort 1: 9 mice.
○ Cohort 2: 26 mice.
○ Cohort 3: 26 mice.

Materials and reagents
Reagent

Type

Manufacturer

Catalog #

Comments

LM-4175 cells expressing
HSV-tk1-GFP-Fluc

Cell line

Original lab

n/a

From original lab

Dulbecco’s modified Eagle’s
medium—low glucose, without
L-glutamine

Cell culture

Sigma–Aldrich

D5546

Original not specified

PBS, without MgCl2 and CaCl2

Buffer

Sigma–Aldrich

D8537

Original not specified

0.05% trypsin/0.48 mM EDTA

Cell culture

Sigma–Aldrich

T3924

Original not specified

50 ml tubes

Labware

Sigma–Aldrich

CLS430290

Original not specified

Fetal bovine serum

Cell culture

Sigma–Aldrich

F0392

Original not specified

L-glutamine

Cell culture

Sigma–Aldrich

G7513

Original not specified

100× pen/Strep

Cell culture

Sigma–Aldrich

P4333

Original not specified

100 mm tissue culture dishes

Labware

Sigma–Aldrich

CLS430167

Original not specified

60 mm tissue culture dishes

Labware

Sigma–Aldrich

CLS430166

Original not specified

Matrigel matrix

Cell culture

Corning

356234

Original from Becton Dickinson
nu

Hsd:Athymic Nude-Foxn1

Mice should be acclimated for 2 weeks
before the start of experiment

8–10 week old female athymic
nude mice

Animal model

Harlan

Ketamine

Chemical

Xylazine

Chemical

Specific brand information will be left up to the discretion of the replicating lab and recorded
later

25 G needle

Labware

Sigma–Aldrich

Z192406

Original not specified

1 ml syringe

Labware

Sigma–Aldrich

Z192090

Original not specified

VivoGlo Luciferin

Reporter assay Promega

P1042

Original not specified

IVIS Imaging System

Instrument

PerkinElmer

200 Series

Living Image software

Software

PerkinElmer

Version 4.3.1

O.C.T. compound (Tissue-Tek)

Buffer

VWR

25,608-930

Original not specified

Procedure
Note
c
c
c
c
c

pMEFs are generated in Protocol 1 with inclusion/exclusion criteria determined in Protocol 2.
pMEFs maintained in: DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin
and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO2.
LM-4175 tumor cells express HSV-tk1-GFP-Fluc and will be sent for mycoplasma testing and STR
profiling as well as screened against a Rodent Pathogen Panel.
LM-4175 maintained in: normal glucose DMEM supplemented with 10% FBS at 37˚C in a humidified
atmosphere at 5% CO2.
Athymic nude mice should be 8–10 weeks old when they arrive and about 10–12 weeks old when
injected with cells.
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1. Cell preparation for injection:
a. LM-4175 tumor cells alone:
i. Prepare 1 × 107 cells/ml of LM-4175 tumor cells in sterile chilled PBS.
1. You will need 0.1 ml (1 × 106 cells) per injection.
2. Adjust cell mixture accordingly for needed number of injections.
ii. Mix cell suspension.
b. LM-4175 tumor cells with pMEFs.
i. Prepare 2 × 107 cells/ml of LM-4175 tumor cells in sterile chilled PBS.
ii. Prepare 2 × 107 cells/ml of Cav1 WT pMEFs, or Cav1 KO pMEFs in sterile chilled PBS.
iii. Mix the two suspensions together to form a 1:1 mixture.
1. You will need 0.1 ml (2 × 106 cells) per injection.
2. Adjust cell mixture accordingly for needed number of injections.
c. Using well-chilled tubes and pipette tips, mix each final cell suspension with an equal amount
(0.1 ml) of Matrigel and store on ice.
2. Anesthetize 10–12 week old female athymic nude mice.
a. House mice under pathogen-free conditions and give autoclaved food and water ad libitum.
b. Anesthetize with 100 mg/kg ketamine and 10 mg/kg xylazine.
3. Using a 25 G needle and 1 ml syringe, aspirate 0.2 ml of Matrigel/cell suspension and inject
subcutaneously at the prepared site.
a. During injection keep the mice warm by lying them on a warming plate designed for animal
experiments.
b. Stretch the abdominal cavity avoiding the formation of wrinkles.
c. Inject Matrigel/cell suspension slowly by introducing the needle as parallel as possible to the
skin. Ensure the Matrigel/cell suspension forms a visible bump under the skin.
d. If injection enters the peritoneum, there will not be a bubble in the skin and instead of
formation of one primary tumor there will be many intraperitoneal tumors. These mice should
be excluded from the experiment and analysis.
i. It is important not to take the needle out of the skin until the Matrigel has gelled. Gelification
takes a very short time at body temperature (∼1 min).
4. Allow mice to recover and keep them warm until they wake up.
5. Maintain mice for 70 days.
a. Measure tumor size twice weekly with precision calipers.
b. Initial tumor formation is defined as the time when the tumor reaches a diameter of 3 mm. The
tumor should never be greater than 10% body weight or exceed 20 mm in any one dimension. If
ulceration or infection at the tumor site, or interference with eating or impairment of
ambulation by the tumor occurs, the animals should be euthanized.
c. Additional euthanasia criteria to ensure no animal suffering (when two or more of these criteria
are detected, monitor the animals for 12 hr, if the condition does not improve, euthanize):
i. Rapid or progressive weight loss (more than 10% in 2 weeks).
ii. Debilitating diarrhea.
iii. Dehydration/reduced skin turgor.
iv. Edema.
v. Sizable abdominal enlargement or ascites.
vi. Hunched posture.
vii. Lethargy.
viii. Labored breathing, nasal discharge.
ix. Bleeding from any orifice.
x. Any condition interfering with daily activities for more than 2 hr (e.g., eating or drinking,
ambulation, or elimination).
xi. Excessive or prolonged hyperthermia or hypothermia.
6. At 70 days (or an earlier time point if the number of mice euthanized in step 5 compromise the
ability to obtain enough mice for analysis), anesthetize each mouse and inject pairs of mice with
150 μl of 17.5 mg/ml luciferin solution intraperitoneally.
a. Anesthetize with 100 mg/kg ketamine and 10 mg/kg xylazine.
b. Prepare solution of luciferin according to manufacturer’s instructions.
c. Within each pairing of mice image, euthanize, dissect, re-image, and freeze tumors (steps
6–10) from mice from different cohorts in parallel (i.e., one from each of the three cohorts,
or one each from cohort 2 and cohort 3) so variations during the procedure are equal across
cohorts.
7. After 20 min post luciferin injection, place in IVIS Imaging System and take ventral views for
photon flux quantification.
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a. To facilitate metastasis detection in axillary/brachial lymph nodes, secure front limbs with
tape, and shield the lower portion of the animal to block bioluminescence from the primary
tumors.
b. Use extended exposures (0.2 s–20 s) for in vivo metastases detection.
c. To detect well-defined in vivo metastases, shield lower portion of the animal to block
bioluminescence from the primary tumors and bladder, and use a 20 s exposure.
8. Euthanize mouse and excise the primary tumor and extract organs.
a. Before euthanasia, inject a second dose of luciferin solution—50 μl of 17.5 mg/ml luciferin
solution intraperitoneally.
b. Wait 20 min, euthanize mouse and quickly excise the primary tumor and extract the following
organs to image for metastasis:
i. Lymph nodes.
ii. Spleen.
iii. Lungs.
iv. Liver.
v. Intestines.
vi. Kidneys.
9. Reimage organs ex vivo in IVIS imaging system.
a. Place all organs in plastic dish (uncovered), with organs separated, for imaging.
b. Reimage organs as quickly as possible after organ dissection.
c. Acquire multiple exposure times to manually quantify every visible metastatic focus.
(Recommend 1, 20, and 60 s exposures, with 2 min as longest exposure time).
d. Small metastatic foci can be detected by adjusting the scale of photon flux in Living Image
software (version 3.2).
10. Cut extracted primary tumors in half and freeze in O.C.T. compound for further analysis (Protocol
4). Randomly select the following number of tumors from each cohort:
a. LM-4175 cells alone—4 tumors.
b. LM-4175 cells co-injected with Cav1 WT pMEFs—7 tumors.
c. LM-4175 cells co-injected with Cav1 KO pMEFs—7 tumors.

Deliverables
■ Data to be collected:
○ Passage of cells, particularly pMEFs, injected in each mouse.
○ Mouse health records (including if euthanasia is required and reason, date of euthanasia, and
date of imaging if it is not 70 days).
○ Twice weekly tumor measurements.
○ All images of mice in vivo to detect primary tumor (compare to Figure 7Cc).
○ All images of excised organs (ex vivo) to detect metastatic foci (compare to Figure 7Cc).
○ Raw photon flux measurements of primary tumor and metastasis in vivo and metastatic foci ex
vivo, including counts of metastatic foci from ex vivo images.
○ Graph of primary tumor growth (photon flux (P/s, ×1010) for all conditions (compare to Figure S7Ca).
○ Graph of metastatic foci (ex vivo bioluminescence) per mouse for all conditions. One graph for
each organ type and for total organs (compare to Figure 7Cb).
■ Sample delivered for further analysis:
○ Preserved primary tumors for further analysis in Protocol 4.

Confirmatory analysis plan
This replication attempt will perform the following statistical analysis listed below:
■ Statistical analysis:
○ Wilcoxon–Mann Whitney test of total metastatic foci counts per mouse by ex vivo
bioluminescence for the following comparisons with the Bonferroni correction:
Note: in order to enable a direct comparison to how the original data was analyzed, uncorrected
tests will also be performed.
1. LM-4175 only to LM-4175 co-injected with Cav1 WT.
2. LM-4175 only to LM-4175 co-injected with Cav1 KO.
3. LM-4175 co-injected with Cav1 WT to LM-4175 co-injected with Cav1 KO.
○ Kruskal–Wallis test of primary tumor growth per mouse by in vivo bioluminescence for all
conditions.
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■ Meta-analysis of effect sizes:
○ Compute the effect sizes of each comparison, compare them against the reported effect size in
the original paper and use a random effects meta-analytic approach to combine the original and
replication effects, which will be presented as a forest plot.

Known differences from the original study
The replication attempt is not including the experimental condition of p190RhoGAP knockdown in
Cav1 KO pMEFs. All known differences, if any, are listed in the materials and reagents section above
with the originally used item listed in the comments section. The comments section also lists if the
source of original item was not specified. All differences have the same capabilities as the original and
are not expected to alter the experimental design.

Provisions for quality control
The pMEFs used in this protocol were assessed for Cav1 status and ECM remodeling capabilities
(SMA levels) in Protocol 2. The cell lines used in this experiment will undergo STR profiling to
confirm their identity and will be sent for mycoplasma testing to ensure there is no
contamination. Additionally, cells will be screened against a Rodent Pathogen Panel to ensure
no contamination prior to injection. Mice will be injected with luciferin, imaged, euthanized,
dissected, re-imaged, and tumors frozen one animal from each cohort done in parallel to have
variations during the procedure equal across cohorts. All of the raw data, including the image
files and quantified metastatic foci, will be uploaded to the project page on the OSF (https://osf.
io/7yqmp) and made publically available.

Protocol 4: examining intratumoral fiber orientation and cell shape in
tumor cells co-injected into nude mice with pMEFs
This experiment tests the effect of Cav1 expression in pMEFs on fiber orientation and cell shape within
the tumor environment. Tumor sections derived from Protocol 3 are immunostained for fibronectin
and smooth muscle actin, and the orientation of the fibers and cell shape are quantified. Fibronectin
fiber orientation is further correlated with the amount of metastasis. It is a replication of experiments
reported in Figure 7Cd and Supplemental Figure S7Cc.

Sampling
■ Experiment has 3 cohorts:
○ Cohort 1: LM-4175 cells alone.
○ Cohort 2: LM-4175 cells co-injected with Cav1 WT pMEFs.
○ Cohort 3: LM-4175 cells co-injected with Cav1 KO pMEFs.
■ Stained for:
○ Fibronectin.
○ SMA.
○ Control staining:
c Isotype control.
c Secondary antibody only control.
■ Experiment will use the following number of primary tumors with 2 sections stained per tumor, with
additional sections for controls, and 5 regions imaged per section for a minimum power of 80%:
○ See power calculations section for details.
c Cohort 1: 4 tumors.
c Cohort 2: 7 tumors.
c Cohort 2: 7 tumors.
■ Experiment will analyze at least the following number of SMA + cells from the following cohorts for
a minimum power of 80%:
○ The original lab collected an average of 10–20 cells/region.
○ The replication will collect 5 regions/tumor.
○ See Power calculations section for details.
c Cohort 1: 85 images.
c Cohort 2: 85 images.
c Cohort 3: 65 images.
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Materials and reagents
Reagent

Type

Manufacturer

Catalog #

Comments

Fluoroshield

Chemical

Sigma–Aldrich

F6182

Included during communication with original
authors. Original lab used Permafluor.

Acetone

Chemical

Specific brand information will be left up to the discretion of the replicating lab and recorded later

Chloroform

Chemical

PBS, without MgCl2 and CaCl2

Buffer

Sigma–Aldrich

D8537

Originally not specified

Bovine serum albumin

Chemical

Sigma–Aldrich

A9647

Originally not specified

Rabbit IgG isotype control

Antibodies Sigma–Aldrich

I5006

Originally not specified

Rabbit anti-fibronectin

Antibodies Sigma–Aldrich

F3648

Stock = 0.5–0.7 mg/ml; Dilute 1:200

Mouse IgG2a isotype control

Antibodies Sigma–Aldrich

M5409

Originally not specified

Mouse anti-α-smooth muscle actin

Antibodies Sigma–Aldrich

A5228

Stock = ∼2 mg/ml; Dilute 1:100

Alexa 594 conjugated donkey
anti-rabbit IgG

Antibodies Jackson Immuno Research

711-545-152

Original lab used goat-anti-rabbit-Cy3

Alexa 647 conjugated donkey
anti-mouse IgG

Antibodies Jackson Immuno Research

715-605-151

Originally not specified

Hoechst stain 33,258

Stain

Sigma–Aldrich

14,530

Dilute 1:1000

Confocal microscope

Instrument

Zeiss

LSM510

Original was Leica SPE (communication with
original authors)

Image acquisition software

Software

Zeiss

ZEN 2009

Originally not specified

Metamorph microscopy automation Software
and imaging analysis software

Molecular Devices

6.2r1

Excel

Microsoft

Software

Procedure
1. Cut primary tumor from Protocol 3 on a microtome with a section thickness of 8 μm and mount on
slides.
a. Cut at least 2 sections from each tumor.
2. Fix and permeabilize sections:
a. Place sections in −20˚C acetone and incubate at −20˚C for 5 min.
b. Place sections in −20˚C acetone:chloroform (1:1) solution and incubate at −20˚C for 5 min.
c. Place sections in −20˚C acetone and incubate at −20˚C for 5 min.
d. Wash sections 2 times in 1× PBS.
3. Incubate sections in 1× PBS supplemented with 2% BSA for 20 min at room temperature. Wash 2
times in 1× PBS.
4. Incubate sections in both primary antibodies diluted in 1× PBS supplemented with 2% BSA
overnight at 4˚C. Include additional sections for controls.
a. Rabbit-anti-fibronectin; use at 1:200 dilution.
b. Mouse-anti-αSMA; use at 1:100 dilution.
c. Control staining conditions:
i. Isotype control; use at same concentration as primary.
ii. secondary antibody only controls.
5. Wash 2 times in 1× PBS.
6. Incubate sections in secondary antibody and Hoechst dye diluted in 1× PBS supplemented with 2%
BSA for 1 hr at 37˚C.
a. Alexa 594 donkey-anti-rabbit; use at manufacturer’s recommended dilution.
b. Alexa 647 donkey-anti-mouse; use at manufacturer’s recommended dilution.
c. Hoechst dye; use at 1:1000 dilution.
7. Randomly image 5 independent regions per section at 20× magnification using a confocal
microscope.
Note: if sections are unable to be imaged due to necrosis, autofluorescence, low fibronectin
deposition, or damage during the staining procedure, take images, and exclude from analysis with
indicated reason.
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a. Total number of regions per tumor is 5 (not including control images).
b. Acquire z-stack for each region with 0.5 μm-thick z-slices.
c. Use a 20× objective with a minimum numerical aperture (NA) of 0.70.
8. Blindly quantify intratumoral orientation of fibronectin fibers and SMA + cells and elliptical form
factor of SMA + cells. For details see Amatangelo and colleagues (Amatangelo et al., 2005).
Note: if images are unable to be evaluated due to necrosis, autofluorescence, low fibronectin
deposition, or damage during the staining procedure, record as such.
a. Overlay z-slices to make reconstituted views of the corresponding 3-D fibers for each region.
b. Subject reconstituted 3-D projections to identical modification and digital filters as described
below using MetaMorph offline 6.2r1 imaging analysis software.
c. Reduce non-specific background with the Flatten Background function by selectively darkening
objects with a pixel area greater than 15.
d. Create a binary image by selecting a 35% threshold at the maximum internal intensity option
using the internal threshold function.
e. Count all fibers recognized, as well as their orientation (angle relative to x-axis) using the
integrated morphometry analysis function. Use auto-threshold for light objects and measure
angle of displayed objects.
f. Approximate relative angles to the nearest 10th degree using the rounding function on
Microsoft’s Excel software and determine the mode angle for each image. Arbitrarily set the
mode angle to 0˚ for each image.
g. Quantify the elliptical form factor (EF = length/breadth) of SMA + cells using the integrated
morphometry analysis function.

Deliverables
■ Data to be collected:
○ Image stacks of fibronectin, SMA, and Hoescht-stained tumor sections for all conditions, including
controls and any images taken, but unable to be analyzed (compare to Figure 7Cc and S7Cb).
○ Raw data and summary data of fibronectin fiber orientation (compare to Figure S7Cc).
○ Raw data and summary data of elliptical form factor for SMA + cells (compare to Figure S7Cc).
○ Raw data and summary data of SMA + cells fiber orientation (compare to Figure S7Cc).

Confirmatory analysis plan
This replication attempt will perform the following statistical analysis listed below:
■ Statistical analysis:
○ Wilcoxon-Mann Whitney test of percent of fibronectin fibers within ± 20˚ per tumor by for the
following comparisons with the Bonferroni correction:
Note: in order to enable a direct comparison to how the original data was analyzed, uncorrected
tests will also be performed.
1. LM-4175 only to LM-4175 co-injected with Cav1 WT.
2. LM-4175 co-injected with Cav1 WT to LM-4175 co-injected with Cav1 KO.
○ Wilcoxon–Mann Whitney test of elliptical form factor per SMA + cells for the following
comparisons with the Bonferroni correction:
1. LM-4175 only to LM-4175 co-injected with Cav1 WT.
2. LM-4175 co-injected with Cav1 WT to LM-4175 co-injected with Cav1 KO.
○ Wilcoxon–Mann Whitney test of percent of SMA + cells fibers within ± 20˚ per tumor by for the
following comparisons with the Bonferroni correction:
1. LM-4175 only to LM-4175 co-injected with Cav1 WT.
2. LM-4175 co-injected with Cav1 WT to LM-4175 co-injected with Cav1 KO.
○ Spearman’s rho correlation of intratumoral fibronectin fibers within ± 20˚ vs number of total
metastasis per mouse (cohorts combined).
■ Meta-analysis of effect sizes:
○ Compute the effect sizes of each comparison, compare them against the reported effect size in
the original paper and use a random effects meta-analytic approach to combine the original and
replication effects, which will be presented as a forest plot.

Known differences from the original study
The replication attempt is not including the experimental condition of p190RhoGAP knockdown in
Cav1 KO pMEFs. All known differences, if any, are listed in the materials and reagents section above,
indicated by an asterisk, with the originally used item listed in the comments section. The comments
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section also lists if the source of original item was not specified. All differences have the same
capabilities as the original and are not expected to alter the experimental design.

Provisions for quality control
Isotype and secondary antibody only controls will be included. If a section or image is unable to be
quantified, due to necrotic damage, autofluroescence, low fibronectin deposition, or damage during
the staining procedure, this data will be excluded from the analysis, similar to the original study, but
recorded. The objective used to acquire the original images, that were subsequently used for the
analysis was a Leica HCX PL APO CS 20×/0.70 IMM UV (communication with original authors). The
replication will use a 20× objective with a minimum NA of 0.70. Images will be blindly and randomly
taken and evaluated, and all of the raw data, including the control images and analysis files, will be
uploaded to the project page on the OSF (https://osf.io/7yqmp) and made publically available.

Power calculations
For additional details on power calculations, please see analysis scripts and associated files on the
Open Science Framework:■ https://osf.io/q3e4u/.

Protocols 1 and 2
Not applicable.

Protocol 3
Total metastatic foci per mouse
Summary of original data (provided by original authors).
Dataset being analyzed

Mean

SD

N

LM-4175 only

2.50

1.975

6

LM-4175 + Cav1 WT pMEFs

28.42

22.24

12

LM-4175 + Cav1 KO pMEFs

11.67

11.10

15

Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007).

Test family
■ t test: means: Wilcoxon–Mann–Whitney test (two groups, one tail), alpha error = 0.0167.
A
Pooled SD Effect size d priori power Group 1 sample size Group 2 sample size

Group 1

Group 2

LM-4175 only

LM-4175 + Cav1 WT pMEFs 18.47

1.403155

80.7%

7

21

LM-4174 only

LM-4175 + Cav1 KO pMEFs 9.58

1.390827*

80.0%*

7

21

LM-4175 +
Cav1 WT pMEFs

LM-4175 + Cav1 KO pMEFs 16.93

0.989463

81.9%

21

21

*A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power.

Primary tumor growth
Summary of original data (provided by original authors).

Dataset being analyzed

Mean

SD

N

LM-4175 only

2.337 × 1010

1.856 × 1010

6

LM-4175 + Cav1 WT pMEFs

2.825 × 1010

3.901 × 1010

13

LM-4175 + Cav1 KO pMEFs

2.312 × 1010

1.368 × 1010

15
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Analysis of original data: (Kruskal–Wallis; performed with GraphPad Prism, version 6.0).
Kruskal–Wallis statistic

p-value

0.8878

0.6415

Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007).

Test family
■ F test: ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05.
Groups

Effect size f

A priori power

Total sample size

LM-4175 only, LM-4175 + Cav1 WT
pMEFs, LM-4175 + Cav1 KO pMEFs

0.504525*

80.0%*

41† (3 groups)

*A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size
that can be detected with the sample size reported and 80% power.
†Since the non-parametric Kruskal–Wallis test will be performed for the analysis instead of an ANOVA, the sensitivity
calculation was performed with a ∼15% adjustment in sample size to calculate the effect size that can be detected
with 80% power. The total sample size of 49, which comes from the total metastatic foci per mouse sample size
calculation, was reduced by ∼15%–41 for this calculation to estimate the detectable effect size.

Protocol 4
Percent of fibronectin fibers within ± 20˚
Summary of original data (obtained from Figure S7Cc).
Dataset being analyzed

N

Mean

SEM

SD

LM-4175 only

5

36.8

0.7

1.565

LM-4175 + Cav1 WT pMEFs

8

50.3

2.3

6.505

LM-4175 + Cav1 KO pMEFs

10

41.5

1.1

3.479

Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007).

Test family
■ t test: Means: Wilcoxon–Mann–Whitney test (two groups, one tail), alpha error = 0.025.
Group 1

Group 2

Pooled SD Effect size d A priori power Group 1 sample size Group 2 sample size

LM-4175 only

LM-4175 + Cav1 WT
pMEFs

5.27

2.559575

82.7%*

4

4*

LM-4175 + Cav1 WT
pMEFs

LM-4175 + Cav1 KO
pMEFs

5.03

1.748808

83.1%

7

7

*7 tumors will be used based on the WT vs KO comparison making the power 94.0%.

Elliptical form factor of SMA + cells
Summary of original data (obtained from Figure S7Cc).
Dataset being analyzed

N

Mean

SEM

SD

LM-4175 only

224

1.70

0.03

0.449

LM-4175 + Cav1 WT pMEFs

1246

2.14

0.03

1.059

LM-4175 + Cav1 KO pMEFs

763

1.68

0.02

0.5524

Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007).
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Test family
■ t test: Means: Wilcoxon–Mann–Whitney test (two groups, one tail), alpha error = 0.025.
Pooled
SD

Effect
size d

A priori
power

Group 1 sample
size

Group 2 sample
size

LM-4175 + Cav1 WT
pMEFs

0.99

0.444072

80.3%

85

85

LM-4175 + Cav1 KO
pMEFs

0.90

0.510625

80.6%

65

65

Group 1

Group 2

LM-4175 only
LM-4175 + Cav1 WT
pMEFs

Percent of SMA + fibers within ± 20˚
Summary of original data (obtained from Figure S7Cc).
Dataset being analyzed

N

Mean

SEM

SD

LM-4175 only

5

33.1

4

8.944

LM-4175 + Cav1 WT pMEFs

8

51.3

2

5.657

LM-4175 + Cav1 KO pMEFs

10

35.3

2

6.325

Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007).

Test family
■ t test: means: Wilcoxon–Mann–Whitney test (two groups, one tail), alpha error = 0.025.
Group 1

Group 2

Pooled SD Effect size d A priori power Group 1 sample size Group 2 sample size

LM-4175 only

LM-4175 + Cav1 WT
pMEFs

7.03

2.588043

83.5%*

4

4*

LM-4175 + Cav1 WT
pMEFs

LM-4175 + Cav1 KO
pMEFs

6.04

2.648198

85.0%†

4†

4†

*7 tumors will be used based on the fibronectin fiber orientation analysis making the power 94.4%.
†7 tumors will be used based on the fibronectin fiber orientation analysis making the power 99.3%.

Correlation of percent of fibronectin fibers within ± 20˚ and number of metastasis
Original data (obtained from original authors).
The shared data contained 27 XY pairs with a calculated Spearman rho of 0.7488, which is missing 3
pairs included in the published analysis, with a Spearman rho of 0.81. The power calculations were
performed on the shared data and Spearman rho, which will give a more conservative sample size to
detect the published value.
Power calculations performed with R software, version 3.1.0 (R Development Core Team, 2014).

Test family
■ Correlation: Spearman’s rho test (one sided), alpha error = 0.05.
Groups

Number of simulations

A priori power

Total sample size

% fibronectin fibers within ± 20˚ and
number of metastasis

10,000*

83.1%

10

*The shared data from XY pairs was randomly sampled from, with replacement, to create simulated data sets with
preserved correlated structure. For a given n (the number of observations) 10,000 simulations were run and
Spearman’s rho was calculated for each simulated data set. The power was then calculated by counting the number
of times p ≤ 0.05 and dividing by 10,000.
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